161 related articles for article (PubMed ID: 21356539)
1. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.
Anastassopoulou CG; Ketas TJ; Depetris RS; Thomas AM; Klasse PJ; Moore JP
Virology; 2011 Apr; 413(1):47-59. PubMed ID: 21356539
[TBL] [Abstract][Full Text] [Related]
2. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
Anastassopoulou CG; Ketas TJ; Sanders RW; Klasse PJ; Moore JP
Virology; 2012 Jul; 428(2):86-97. PubMed ID: 22520838
[TBL] [Abstract][Full Text] [Related]
3. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.
Anastassopoulou CG; Ketas TJ; Klasse PJ; Moore JP
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5318-23. PubMed ID: 19289833
[TBL] [Abstract][Full Text] [Related]
4. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
[TBL] [Abstract][Full Text] [Related]
5. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
[TBL] [Abstract][Full Text] [Related]
6. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
7. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
9. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
10. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM; Hu Z; Paredes R; Leopold KE; Putcharoen O; Schure AL; Mazur N; Coakley E; Su Z; Gulick RM; Kuritzkes DR
J Virol; 2012 Jun; 86(12):6416-26. PubMed ID: 22491471
[TBL] [Abstract][Full Text] [Related]
11. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
[TBL] [Abstract][Full Text] [Related]
12. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
[TBL] [Abstract][Full Text] [Related]
13. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
14. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.
Dimonte S; Babakir-Mina M; Mercurio F; Di Pinto D; Ceccherini-Silberstein F; Svicher V; Perno CF
Virus Res; 2012 Sep; 168(1-2):73-83. PubMed ID: 22732432
[TBL] [Abstract][Full Text] [Related]
15. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
16. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.
Berro R; Sanders RW; Lu M; Klasse PJ; Moore JP
PLoS Pathog; 2009 Aug; 5(8):e1000548. PubMed ID: 19680536
[TBL] [Abstract][Full Text] [Related]
17. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region.
Labrosse B; Treboute C; Alizon M
J Virol; 2000 Mar; 74(5):2142-50. PubMed ID: 10666243
[TBL] [Abstract][Full Text] [Related]
19. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
Berro R; Klasse PJ; Jakobsen MR; Gorry PR; Moore JP; Sanders RW
Virology; 2012 Jun; 427(2):158-65. PubMed ID: 22424737
[TBL] [Abstract][Full Text] [Related]
20. Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.
Dimonte S; Mercurio F; Svicher V; D'Arrigo R; Perno CF; Ceccherini-Silberstein F
Retrovirology; 2011 May; 8():33. PubMed ID: 21569409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
